Document:

EXHIBIT 10.19

 

CONFIDENTIAL TREATMENT REQUESTED 

 

The confidential portions of this exhibit have been filed
separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2
of the Securities and Exchange Act of 1934 as amended. 

 

REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN [***].

 

EXCLUSIVE LICENSE AGREEMENT

 

This EXCLUSIVE LICENSE AGREEMENT (this "Agreement")
is entered into as of the last date below written (the "Effective Date"), by and between SARA MANTERO, Ph.D.
("Mantero"); MARIA ADELAIDE ASNAGHI ("Asnaghi") (Mantero and Asnaghi are collectively
referred to herein as "Licensor"); HARVARD BIOSCIENCE, INC., a Delaware corporation ("Licensee").

 

Recitals:

 

A.    Licensor
is the inventor of certain processes and devices that allow for the migration of organic cells into tissue samples while being
incubated in a specialized bioreactor (the "Technology").

 

B.     The
Technology has proven beneficial medical uses in organ transplant as well as the potential for use in other areas.

 

C.     Subject
to the terms of this Agreement, Licensee desires to obtain a license from Licensor and Licensor desires to provide to Licensee
an exclusive license to make, use, have made, sell, offer to sell, import, manufacture, market and distribute the Technology and
related improvements.

 

THEREFORE, for good and valuable consideration, the receipt
and adequacy of which is hereby recognized by the parties, the parties agree as follows:

 

ARTICLE: 1

DEFINITIONS

 

1.1           "Affiliate"
means any entity controlled by, under common control with, or controlling Licensee through voting stock or its board of directors
or other supervisory board.

 

1.2           "Authorized
Person" means Licensee's or its Affiliate's employees, officers, legal counsel, members of Licensee's board of directors
or supervisory board, and independent contractors, each of whom Licensee shall have obtained a written agreement from to comply
with the obligations of Licensee under this Agreement.

  

	 	Page 1	Execution Version
	 	 	Exclusive License Agreement

 

    	 

    	 

    

  

1.3          "Confidential
Information" means any proprietary information of or regarding Licensor or Licensee, including the Know-How and any trade
secrets included within the Improvements, and all other, techniques, inventions, ideas, and processes; any data or information
relating to any work in process, or future development plans; and any engineering, manufacturing, marketing, servicing, financial
or personnel matter or information relating to Licensor or Licensee in oral, written, graphic or electronic form. Confidential
Information may also include information disclosed to a disclosing party by third parties. Confidential Information will not, however,
include any information which:

 

(a)          was
publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party;

 

(b)          becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party through no
action or inaction of the receiving party;

 

(c)          becomes
publicly known as a result of having been included in a patent application relating to the Technology;

 

(d)          does
not pertain to the Technology and is already in the possession of the receiving party at the time of disclosure by the disclosing
party as shown by the receiving party's files and records immediately prior to the time of disclosure;

 

(e)          is
obtained by the receiving party from a third party without a breach of such third party's obligations of confidentiality;

 

(f)          does
not pertain to the Technology and is independently developed by the receiving party without use of or reference to the disclosing
party's Confidential Information, as shown by documents or other competent evidence in the receiving party's possession; or

 

(g)          is
required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written
notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public
disclosure.

 

1.4          "Hardware"
means any hardware or equipment owned by Licensor that is required to assemble, maintain or use the bioreactors associated with
the Technology as of the Effective Date.

 

1.5          "Improvements"
mean any Intellectual Property developed after the Effective Date by either Mantero or Asnaghi or any third party affiliated with
Mantero or Asnaghi that constitutes an improvement or enhancement of the functions of the Technology, that is associated to the
Technology and that relates :to a bioreactor device able to feed and repopulate a rotating tubular structure, with the exclusion
of different or new functions relating to generation of electrical fields, pressure fields and fluid dynamic fields.

  

	 	Page 2	Execution Version
	 	 	Exclusive License Agreement

 

 

    	 

    	 

    

 

 

1.6          "Intellectual
Property" means (a) all inventions (whether patentable or un-patentable and whether or not reduced to practice); all improvements
thereto, and all patents, patent applications, and invention disclosures, together with all re-issuances, continuations, continuations-in-part,
divisions, renewals, revisions, reissues, extensions and reexaminations thereof, (b) all works of authorship, all copyrights therein,
and all applications, registrations, and renewals in connection therewith, (c) all know-how and trade secrets; (d) all software
in source or object code form; and (e) all copies and tangible embodiments of the foregoing (in whatever form or medium).

 

1.7          "Know-How"
means any and all technical data, user guidelines, protocols, trade secrets, drawings, information, knowledge and other Intellectual
Property that relates to the Technology or the manufacture, marketing, registration, purity, quality, potency, safety or efficacy
of the Technology.

 

1.8          "Licensed
Processes" means any processes that relate to the Know-How.

 

1.9          "Licensed
Products" means any bioreactors included within the Know-How.

 

1.10        “Licensed
Services" means any services whereby a Licensed Process is performed for another.

 

1.11        "Licensed
Technology" means the Know-How, Licensed Processes, Licensed Products, Licensed Services, Patent Rights and/or Improvements.

 

1.12        "Patent
Rights" mean all of the following:

 

(a)          any
United States and/or foreign patents and/or patent applications related to the Technology or Improvements in which either Mantero
or Asnaghi is listed as an inventor;

 

(b)          United
States and foreign patents issued from the applications described in (a) and/or from divisionals and continuations of these applications;

 

(c)          United
States continuation in part applications and foreign continuation in part applications, and the resulting patents, based on the
United States and/or foreign applications described in (a);

 

(d)          claims
of all foreign patent applications, and of the resulting patents, which are directed to subject matter specifically described in
the United States patents and/or applications described in (a), (b) or (c) above; and

 

(e)          any
reissues of patents described in (a), (b), (c) or (d) above.

 

1.13        "Recipient"
means the party who receives Confidential Information under this Agreement, including Authorized Persons.

 

1.14        "Territory"
means world-wide and everywhere.

  

	 	Page 3	Execution Version
	 	 	Exclusive License Agreement

  

    	 

    	 

    

  

ARTICLE: 2

LICENSE GRANT

 

2.1           License.
Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive, perpetual and irrevocable
license to make, use, have made, sell, offer to sell, import, manufacture, market and distribute the Licensed Technology within
the Territory. Licensee shall appoint the. company SKE S.r.l. as exclusive distributor of the Licensed Technology in Italy at the
conditions to be separately agreed between the parties.

 

2.2           Sublicenses.
Licensee will have the right to grant one or more sublicenses under this Agreement without the prior written consent of Licensor.

 

2.3           Reservation
of Rights. Licensor reserves the right to practice the Patent Rights and further develop the Technology for its own non-commercial
research purposes. Licensor will not have the right to grant sublicenses of these rights without the prior written consent of Licensee.

 

2.4           Know-How
and Hardware Transfer. Licensor will provide Licensee with access to all Know-Flow existing and as may be developed from time
to time. In addition, Licensor will provide Licensee with access to the actual rotating bioreactor used in, and all data related
thereto, the engineered airway transplantation. Licensor hereby assigns, transfers and conveys to Licensee all of Licensor's interests
in and to the Hardware.

 

2.5           License
to Use Names. Licensee is hereby granted the world-wide, perpetual and irrevocable right to disclose and use the names of Licensor
and University in connection with promoting, advertising, marketing, licensing and/or selling Licensed Products and products that
were formerly Licensed Products, as long as such disclosure and usage accurately describes their involvement in the development
of the Licensed Technology.

  

ARTICLE: 3

TERM AND TERMINATION

 

3.1           Termination.
This Agreement will terminate upon the later of: a) the date of the last to expire of any Patent Rights, or b) seven (7) years
from the Effective Date if no Patent Rights are in existence as of such date.

 

3.2           Failure
to Pay Royalties. If Licensee fails to pay Licensor any royalties due and payable under this Agreement, then Licensor may terminate
this Agreement upon ninety (90) days prior written notice unless Licensee pays Licensor within the ninety (90) day period all such
uncontested royalties and interest due and payable. Upon the expiration of the ninety (90) day period, if Licensee has not paid
all such royalties and interest due and payable, the rights, privileges and licenses granted to Licensee under this Agreement will
immediately terminate.

 

3.3           Effects
of Termination. Termination of this Agreement, for whatever reason, will not affect any rights of either party that have accrued
prior to the termination of this Agreement, though no additional rights will accrue following the termination. If this Agreement
is terminated as a result of Licensor's breach, then Licensor will be deemed to have forfeited and assigned to Licensee all right,
title and interest in and to the Licensed Technology and Licensor hereby grants Licensee the power of attorney to execute such
documents as may be required to effectuate such assignment of the Licensed Technology as Licensee deems appropriate.

  

	 	Page 4	Execution Version
	 	 	Exclusive License Agreement

  

    	 

    	 

    

  

ARTICLE: 4

ROYALTIES

 

4.1          Marketing
and Sales Efforts. Licensee agrees to use commercially reasonable efforts to market and sell Licensed Products.

 

4.2          Royalty
Payment. For the rights, privileges and licenses granted hereunder, Licensee shall pay to Licensor the royalties described
in Exhibit A.

 

4.3          Payments
and Reports.

 

(a)          Licensee,
within forty-five (45) days after June 30 and December 31 of each year, will deliver to Licensor true and accurate reports, giving-such
particulars of the business conducted by Licensee during the preceding six-month period under this Agreement as shall be pertinent
to a royalty accounting under this Agreement.

 

(b)          With
each such report submitted, Licensee shall pay to Licensor the royalties due and payable under this Agreement. If no royalties
are due, Licensee will state this in writing within such time period.

 

4.4          Products
to University. Licensee will provide University with Licensed Products for research use only at University at a price equal
to Licensee's cost, plus twenty (20%) percent. The parties acknowledge that no royalties will be paid to Licensor with respect
to such sales to University. In addition, Licensee will provide University with up to three (3) Licensed Products, without charge,
to be used for research purposes only at University. University agrees not to resell any Licensed Products that it received from
Licensee.

  

ARTICLE: 5

TRADEMARKS

 

5.1          Acknowledgement.
Licensor acknowledges that Licensee will have the authority to market the Licensed Technology under any trademarks that it desires.
Licensor acknowledges Licensee's sole right, title and interest in and to any such trademarks and agrees not to claim any title
or interest in such trademarks or any right to use the trademarks except as may be permitted by Licensee in writing.

 

5.2          Variations.
Licensor will not at any time permit the adoption or use, without Licensee's prior written consent, of any variation of any trademarks
likely to be confused with or similar to any trademarks used by Licensee to market the Licensed Technology. If Licensee consents
to any such variation, then Licensor agrees that Licensee will own such new mark.

 

5.3          Future
Cooperation. Licensor will, during and after the term of this Agreement, execute such documents as Licensee may request from
time-to-time to ensure that all right, title and interest in and to the trademarks used in association with the marketing of the
Licensed Technology reside and remain with Licensee or any other entity determined by Licensee.

  

	 	Page 5	Execution Version
	 	 	Exclusive License Agreement

  

    	 

    	 

    

  

ARTICLE: 6

WARRANTIES

 

6.1          Warranties.
Licensor represents and warrants to Licensee that:

 

(a)          Licensor
has the sole, exclusive arid unencumbered right to grant the licenses and rights granted in this Agreement to Licensee;

 

(b)          there
are no other agreements with any third parties that relate to the Licensed Technology that would conflict with the rights granted
by this Agreement;

 

(c)          to
the best of Licensor's knowledge, the Licensed Technology does not in any way infringe upon any intellectual property rights of
any third party;

 

(d)          to
the best of Licensor's knowledge, no governmental or other third party authorizations, permits or licenses are required to use
or sell the Licensed Technology; and

 

(e)          Licensor
will not assign any interests in any Improvements to any third party or otherwise take any actions to encumber Licensee's interest
in the Technology or Improvements as granted by this Agreement.

 

6.2          Technology
Information and Access. Upon request by Licensee from time-to-time, Licensor will, within a reasonable period of time thereafter
not later than thirty (30) days after such request, deliver to Licensee copies of reasonable documentation describing the Licensed
Technology as it is reasonably related to the scope of Licensee's efforts to market or sell the Licensed Technology. Licensor grants
Licensee the rights to copy; modify, distribute and create derivative works from any such documentation. Licensor will give access
to and use reasonable efforts to keep Licensee appraised of, all ongoing and future Licensed Technology created by Licensor. Licensor
will reasonably cooperate with and provide advice to Licensee with respect to the implementation of the Licensed Technology. Licensor
will at all times provide Licensee with access to Licensor's patent applications related to the Licensed Technology and notify
Licensee when any patents issue thereon.

 

6.3          Indemnification.
Licensor will indemnify and hold harmless Licensee and its respective employees, agents, partners, officers and directors from
and against any claims, losses, liabilities or damages (including actual attorneys' fees and expenses) incurred or sustained by
Licensee arising out of or in connection with any fraudulent or grossly negligent breach of any representation, covenant, warranty
or obligation of Licensor under this Agreement.

  

ARTICLE: 7

 LICENSED INTELLECTUAL PROPERTY
RIGHTS ENFORCEMENT

 

7.1          Infringement
by Third Parties. Licensor will notify Licensee promptly of any infringement or unauthorized use of the Licensed Technology
by others of which Licensor becomes aware. Licensee will have the sole right, at its expense, to bring any action on account of
any infringement or unauthorized use of the Licensed Technology of which it becomes aware, and Licensor will cooperate with Licensee,
as Licensee may request, at Licensee's expense, in connection with any such action brought by Licensee. Licensee will retain any
and all damages, settlement and/or compensation paid in connection with any such action brought by Licensee.

 

	 	Page 6	Execution Version
	 	 	Exclusive License Agreement

  

    	 

    	 

    

  

Licensor hereby assigns to Licensee any and
all causes of action Licensor may have for any past, present or future infringement of any rights associated with the Licensed
Technology.

 

7.2           Defending
Against Claims by Third Parties. Licensee will have the sole right, at its expense, to defend and settle for other than money
damages any action that may be commenced against Licensee or Licensor alleging that the Licensed Technology infringes any rights
of third parties. If Licensee does not give notice to Licensor of its intent to defend or settle such action within thirty (30)
calendar days after notice from Licensor of such alleged infringement, Licensor may defend the action, at its expense, provided
that no settlement will be made without the prior written approval of Licensee and Licensor will advise Licensee periodically of
the status of the action and promptly of any material developments. Licensee reserves the right to participate at any time in such
proceedings.

 

7.3           Patent
Maintenance. Licensee, at Licensee's sole expense, will have the sole and exclusive right, in Licensee's sole and absolute
discretion, to apply for, prosecute, or cause the issuance, amendment, abandonment, maintenance, re-examination or reissue of any
patents included in the Licensed Technology.

 

7.4           Cooperation.
Licensor further covenants and agrees that it shall, at any time, upon Licensee's request and at Licensee's expense, testify in
any legal proceeding, execute and deliver any agreement, document, certificate or instrument and generally do all that is possible
or that Licensee deems may be necessary or desirable to secure or maintain the protection of the Intellectual Property associated
with the Licensed Technology.

 

ARTICLE: 8

CONFIDENTIALITY

 

8.1           Non-Use
and Non-Disclosure. Neither party shall use any Confidential Information except to exercise its rights and perform its obligations
under this Agreement. Neither party shall disclose any Confidential Information of the other party to third parties or to such
party's employees, except to those employees of the receiving party with a need to know. Notwithstanding the above; either party
may disclose information on a "need-to-know" basis to potential business associates with the approval of the other party,
which will not be unreasonably withheld.

 

8.2           Maintenance
of Confidentiality. Each party shall take reasonable measures to protect the secrecy of and avoid disclosure and unauthorized
use of the Confidential Information of the other party and of any Confidential Information associated with any trade secrets included
within the Licensed Technology. Without limiting the foregoing, each party shall take at least those measures that it takes to
protect its own most highly confidential information. 

 

8.3           Permitted
Disclosures. Nothing in this Agreement will prevent Licensee from disclosing any information, including Confidential Information,
in any patent application or related document it may elect to file. Recipient may only disclose the Confidential Information to
an Authorized Person.

 

	 	Page 7	Execution Version
	 	 	Exclusive License Agreement

  

    	 

    	 

    

  

ARTICLE: 9

NOT A FRANCHISE AGREEMENT

 

LICENSEE AND LICENSOR AGREE THAT THIS AGREEMENT IS NOT A FRANCHISE
AGREEMENT, AS SUCH AGREEMENTS ARE DEFINED UNDER THE STATUTES AND REGULATIONS OF THE UNITED STATES AND APPLICABLE STATE LAW, AND
THEREFORE THAT THIS AGREEMENT IS NOT SUBJECT TO THOSE STATUTES AND REGULATIONS. LICENSEE AND LICENSOR FURTHER AGREE THAT EACH WILL
EXECUTE ANY DOCUMENTS AND GIVE ANY TESTIMONY WHICH IS NECESSARY TO AVOID HAVING THIS AGREEMENT CONSTRUED AS A FRANCHISE AGREEMENT.

 

ARTICLE: 10

JURISDICTION AND DISPUTES

 

10.1        Choice
of Law. The rights and obligations of the parties under this Agreement shall be governed by the laws of Italy.

 

10.2        Disputes.
In the event of any dispute, controversy or claim arising out of or relating to this Agreement, or to the breach or termination
hereof (a "Dispute"), the parties agree to resolve the same as follows:

 

(a)          The
parties to the Dispute shall initially attempt to resolve it through consultations and negotiations.

 

(b)          If
the Dispute has not been resolved amicably within thirty (30) days after any party provides notice thereof, unless the parties
agree otherwise, the Dispute shall be resolved by a single arbitrator in a final and binding arbitration that will be conducted
in Milan, Italy in accordance with the Arbitration Rules of the Chamber of Commerce of Milan, as in effect on the Effective Date
(the "Milan Rules"). The International Centre for Dispute Resolution ("ICDR") shall serve
as the appointing authority. If the parties cannot agree on the arbitrator then an arbitrator experienced in matters similar to
the Dispute will be chosen by ICDR. The language to be used in the arbitration proceeding shall be English. The arbitration shall
be administered by the ICDR under the Milan Rules. The arbitrator shall render a written award stating the reasons for the decision.
An arbitration award or decision may be entered by any court of competent jurisdiction, or application may be made to such a court
for judicial acceptance of the award or decision and any appropriate order, including enforcement. All direct costs of an arbitration
proceeding under this Section, including fees and expenses of arbitration, shall be borne equally by the parties hereto. All other
costs, including counsel and witness fees, shall be borne by the party incurring them.

  

	 	Page 8	Execution Version
	 	 	Exclusive License Agreement

 

    	 

    	 

    

  

(c)          Each
of the parties hereto consents to the submission of any Dispute for settlement by final and binding arbitration in accordance with
paragraph (b) above. Such consent shall satisfy the requirements for an "agreement in writing" pursuant to Article II
of the United Nations Convention on the Recognition and Enforcement of Foreign Arbitration Awards, done at New York on June 10,
1958.

 

(d)          Each
of the parties hereby undertakes to carry out without delay the provisions of any arbitration award or decision.

  

ARTICLE: 11

GENERAL PROVISIONS

 

11.1        Integration.
With respect to the subject matter of this Agreement, this Agreement constitutes the entire understanding between the parties and
supersedes any prior discussions, negotiations, agreements and understandings.

 

11.2        Notice.
All notices and other communications required or permitted under this Agreement will be in writing and will be deemed given when
delivered personally or by registered or certified mail, return receipt requested, addressed as follows (or any other address that
is specified in writing by either party):

 

To Licensor:

 

Sara Mantero

Dipartimento di Bioingegneria

Politecnico di Milano

Via Golgi 39 (Ed.34 - piano IV)

20133 Milan

Italy

 

Maria Adelaide Asnaghi

Via Piave 54

20036 Meda (MI)

Italy

 

To Licensee:

 

Harvard Bioscience, Inc.

84 October Hill Road

Holliston, Massachusetts 01746

United States of America

 

With a copy to:

 

Jaffe, Raitt, Heuer & Weiss, P.C.

Attn: Sara M. Kruse, Esq.

27777 Franklin Rd., Suite 2500

Southfield, Michigan 48034

United States of America

 

	 	Page 9	Execution Version
	 	 	Exclusive License Agreement

 

    	 

    	 

    

  

11.3         Severability.
Whenever possible, each provision of this Agreement will be interpreted in such a way as to be effective and valid under applicable
law. If a provision is prohibited by or invalid under applicable law, it will be ineffective only to the extent of such prohibition
or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

 

11.4         Assignments.
No assignment of this Agreement or of any right or obligation under this Agreement will be made by Licensor or by Licensee without
the prior written consent of the other party, such consent not to be unreasonably withheld. Further, Licensee may assign its rights
under the Agreement without the prior written consent of Licensor so long as Licensee remains responsible for any obligations in
respect of this Agreement.

 

11.5         Waiver.
Either party's failure to exercise a right or remedy will not operate as a waiver of any of such party's rights or remedies or
the other party's obligations under this Agreement and will not constitute a waiver of its right to declare an immediate or a subsequent
default.

 

11.6         Amendments.
The terms of this Agreement may not be varied or modified in any manner, except in a subsequent writing executed by an authorized
representative of both parties.

 

11.7         Independent
Contractors. In its relationship under this Agreement, each party is an independent contractor. Nothing in this Agreement on
its own will be construed such that

 

11.8         Survival.
The following will survive the termination of this Agreement: Articles 1, 5, 8, 9, 10 and 11 and Sections 2.5, 3.3 and 6.3.

 

11.9         Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original agreement, but all of which
will be considered one instrument and will become a binding agreement when one or more counterparts have been signed by each of
the parties and delivered to the other. A facsimile of this document bearing a party's signature or a printed copy of the original,
signed document scanned in .pdf or .tif format will have the same legal force and effect as an, original of Such signature and
will be treated as an original document for evidentiary purposes.

 

11.10       Force
Majeure. Neither party will be deemed to be in default or otherwise responsible for delays or failures in performance resulting
from acts of God, acts of war or civil disturbance, epidemics, governmental action or inaction, fires, earthquakes, unavailability
of labor, materials, power or communication, or other causes beyond their reasonable control.

 

11.11       No
Third-Party Beneficiaries. This Agreement will not confer any rights or remedies upon any third-party, other than the parties
to this Agreement and their respective successors and permitted assigns.

 

	 	Page 10	Execution Version
	 	 	Exclusive License Agreement

  

    	 

    	 

    

 

11.12       Titles.
Titles and headings to Sections in this Agreement are inserted for convenience of reference only and are not intended to affect
the interpretation or construction of the Agreement.

 

11.13       Ambiguity
Not to Be Construed Against Drafter. Each party to this Agreement has been involved in its drafting and negotiation. No rule
of law that ambiguity in an agreement will be construed against the drafter will be applied in interpreting this Agreement.

 

[SIGNATURES ON NEXT PAGE]

 

	 	Page 11	Execution Version
	 	 	Exclusive License Agreement

 

    	 

    	 

    

 

Agreed as of the date last below written:

 

	Licensor:	 	Licensee:
	 	 	 
	Mantero:	 	HARVARD BIOSCIENCE, INC.,
	 	 	a Delaware corporation
	 	 	 
	By:  	/s/ Sara Mantero	 	By:  	/s/ David Green
	 	     SARA MANTERO, Ph.D.	 	 

	 	 	Print Name:   	David Green

 

	Dated:  	 	 	Its:  	President
	 	 	 
	Asnaghi:	 	Dated:  	5th August, 2009

 

	By:  	/s/ Maria Adelaide Asnaghi	 	 
	 	    MARIA ADELAIDE ASNAGHI	 	 
	 	 	 
	Dated:  	6th Aug 2009	 	 

 

	 	Page 12	Execution Version
	 	 	Exclusive License Agreement

 

    	 

    	 

    

 

Exhibit A

 

Royalties

 

1.       Within
ten (10) days from the Effective Date, Licensee will pay Licensor Thirty Five Thousand and 00/100 ($35,000.00) United States Dollars.

 

2.       For
any Licensed Products that shall be sold in the seven (7) years from the Effective Date and that are not then protected under any
Patent Rights, Licensee will pay Licensor [***] percent of Licensee's Net Sales of such Licensed Products. If this Agreement terminates
during the seven (7) year period where royalties on a particular Licensed Product are required to be paid under this Section 2,
then the obligation to pay royalties with respect to such Licensed Product only will continue until the completion of the seven
(7) year period for which royalties would have otherwise been required to be paid but for the termination of this Agreement,

 

3.       For
any Licensed Products that are then protected under any Patent Rights, Licensee will pay Licensor [***] percent of Licensee's Net
Sales of such Licensed Products for the life of the patent.

 

4.       Until
the date that is seven (7) years from the Effective Date, Licensee will pay Licensor [***] percent of Licensee's Net Sales from
any products that simultaneously meet all of the following criteria ("Inspired Products"): 1) the products are
not Licensed Products, 2) the products were developed by Licensee following the Effective Date, and 3) the products, in Licensee's
and Licensor's opinion, implement the working principles of the Licensed Products, If this Agreement terminates during the seven
(7) year period where royalties on a particular Inspired Product are required to be paid under this Section 4, then the obligation
to pay royalties with respect to such Inspired Product only will continue until the completion of the seven (7) year period for
which royalties would have otherwise been required to be paid but for the termination of this Agreement.

 

5.       For
purposes of clarity, royalties on the sale of a single product cannot be payable under more than one (1) of Sections 2, 3 or 4
above.

 

6.       If
Licensee desires to license any Intellectual Property from any third parties for use in association with a Licensed Product or
Inspired Product, then Licensee may reduce any royalty owed to Licensor under this Agreement in association with any Licensed Products
or Inspired Products that incorporate such third parties' Intellectual Property to a total percentage that will be the greater
of: a) X- [***] *Y, or b) [***] *X, where:

 

X = The percentage royalty based on Net Sales otherwise
due to Licensor for Sale of a Licensed Product or Inspired Product as per this Agreement; and

 

Y = The aggregate percentage of royalty based on Net
Sales to be paid to the third parties for Sale of a Licensed Product or Inspired Product that also includes the third parties'
Intellectual Property.

 

*** CONFIDENTIAL TREATMENT REQUESTED

 

	 	Page 13	Execution Version
	 	 	Exclusive License Agreement

 

    	 

    	 

    

 

Licensee will use reasonable efforts to negotiate licenses with
third parties that require the least possible reduction of Licensor's royalties.

 

7.       Notwithstanding
paragraph 6 of this Exhibit A above, in the event that the aggregate percentage of royalties to be paid by Licensee to
Licensor and all other third parties with respect to the Sale of a Licensed Product or Inspired Product, taking into account
any adjustments set forth above or in such third party agreements, exceeds [***] percent of Licensee's Net Sales of such
Licensed Product or Inspired Product, Licensee shall have the further right to reduce the royalty otherwise payable to
Licensor and such third parties, on a pro rata basis, such that the aggregate royalties do not exceed [***] percent of
Licensee's Net Sales with respect to such Licensed Product or Inspired Product. Any reductions made in accordance with this
paragraph 7 shall be made on a pro-rata basis based on the royalty payments that would have been owed if no adjustments
had been made.

 

8.       All
payments to Licensor will be made fifty (50%) percent to Mantero and fifty (50%) percent to Asnaghi.

 

9.       "Net
Sales" means the gross revenues actually received by Licensee from Sale less sales and/or use (or similar) taxes
actually paid, import and/or export duties actually paid. For purposes of clarity, "Net Sales" do not include
revenues received for equipment sold separately by Licensee which does not qualify as a Licensed Product or Inspired Product
by itself.

 

10.     "Sale"
means to sell, transfer, lease or otherwise dispose.

  

*** CONFIDENTIAL TREATMENT REQUESTED

  

	 	Page 14	Execution Version
	 	 	Exclusive License AgreementExhibit 10.1

 

AMENDMENT TO PROMISSORY NOTES

 

This AMENDMENT TO PROMISSORY
NOTES (this “Amendment”) is made effective as of the 27th day of December, 2012, between Israel Growth Partners
Acquisition Corp., a Delaware corporation (the “Company”), and Moorland Lane Partners, LLC, a Delaware limited
liability company (“Moorland”). All capitalized terms used but not defined herein shall have the respective
meanings given to such terms in the Notes (as defined herein).

 

Recitals

 

A.On December 27,
2010, the Company issued a promissory note to Moorland in the principal amount of $35,000 (the “First 2010 Note”),
which First 2010 Note has a maturity date of December 27, 2012 (the “First 2010 Note Maturity Date”).

 

B.On July 1, 2010,
the Company issued a promissory note to Moorland in the principal amount of $50,000 (the “Original Second 2010 Note”),
which Original Second 2010 Note had a maturity date of July 1, 2011 (the “Original Second 2010 Note Maturity Date”).

 

C.On December 14,
2011, the Company and Moorland entered into the First Amendment to Promissory Note with respect to the Original Second 2010 Note
pursuant to which the Original Second 2010 Note Maturity Date was extended to July 1, 2012 (the “First Amendment”).

 

D.On August 21,
2012, the Company and Moorland entered into the Second Amendment to Promissory Note with respect to the Original Second 2010 Note
(the “Second Amendment”) pursuant to which the Original Second 2010 Note Maturity Date was further extended
to March 1, 2013 (the “Second 2010 Note Maturity Date” and together with the First 2010 Note Maturity Date,
the “Maturity Dates”).

 

E.The Original
Second 2010 Note, as amended by the First Amendment and the Second Amendment, is referred to herein as the “Second 2010
Note,” and the Second 2010 Note and the First 2010 Note are together referred to herein as the “Notes”.

 

F.The Company and
Moorland desire to amend the terms of the Notes as set forth herein.

 

NOW, THEREFORE, the
Company and Moorland hereby agree as follows:

 

1.Maturity Dates.
The respective Maturity Dates of each the Notes is hereby extended to June 30, 2013.

 

2.Waiver.
Moorland hereby unconditionally and irrevocably waives any Event of Default that may have arisen under either of the Notes as a
result of the failure by the Company to repay the principal and accrued interest on the Notes on or prior to the First 2010 Note
Maturity Date or the Second 2010 Note Maturity Date, respectively. The foregoing waiver shall not be deemed to be a waiver by Moorland
of any other covenant, condition or obligation on the part of the Company under the Notes, except as set forth in this paragraph.

 

3.Amendment.
Except as modified herein, the Notes are and shall remain in full force and effect in accordance with its terms.

 

4.Counterparts.
This Amendment may be executed in counterparts, including by facsimile or PDF, each of which when so executed and delivered shall
be deemed an original, and such counterparts together shall constitute only one original.

 

[SIGNATURES APPEAR ON FOLLOWING PAGE]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties have executed
this Amendment as of the date first set forth above.

 

	 	ISRAEL GROWTH PARTNERS ACQUISITION CORP.
	 	 	 	 
	 	By: 	/s/ Craig Samuels	 
	 	Name:	Craig Samuels	 
	 	Title:	President and Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	MOORLAND LANE PARTNERS, LLC
	 	 
	 	By:	/s/ Mitchell Metzman	 
	 	Name:	Mitchell Metzman	 
	 	Title:	Partner	 

 

    	Signature Page to Amendment to Promissory Notes

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]